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BACKGROUND: The common intronic deletion, MYBPC3Δ25, detected in 4% to 8% of South Asian populations, is reported to be 
associated with cardiomyopathy, with ≈7-fold increased risk of disease in variant carriers. Here, we examine the contribution 
of MYBPC3Δ25 to hypertrophic cardiomyopathy (HCM) in a large patient cohort.
METHODS: Sequence data from 2 HCM cohorts (n=5393) was analyzed to determine MYBPC3Δ25 frequency and co-
occurrence of pathogenic variants in HCM genes. Case-control and haplotype analyses were performed to compare variant 
frequencies and assess disease association. Analyses were also undertaken to investigate the pathogenicity of a candidate 
variant MYBPC3 c.1224-52G>A.
RESULTS: Our data suggest that the risk of HCM, previously attributed to MYBPC3Δ25, can be explained by enrichment of a 
derived haplotype, MYBPC3Δ25/−52, whereby a small subset of individuals bear both MYBPC3Δ25 and a rare pathogenic variant, 
MYBPC3 c.1224-52G>A. The intronic MYBPC3 c.1224-52G>A variant, which is not routinely evaluated by gene panel or 
exome sequencing, was detected in ≈1% of our HCM cohort.
CONCLUSIONS: The MYBPC3 c.1224-52G>A variant explains the disease risk previously associated with MYBPC3Δ25 in the 
South Asian population and is one of the most frequent pathogenic variants in HCM in all populations; genotyping services 
should ensure coverage of this deep intronic mutation. Individuals carrying MYBPC3Δ25 alone are not at increased risk of 
HCM, and this variant should not be tested in isolation; this is important for the large majority of the 100 million individuals of 
South Asian ancestry who carry MYBPC3Δ25 and would previously have been declared at increased risk of HCM.
Key Words: exome ◼ genotype ◼ haplotypes ◼ humans ◼ introns
See Editorial by Sadayappan et al
Hypertrophic cardiomyopathy (HCM) is the most com-mon inherited cardiac condition, affecting at least ≈1:500 individuals.1 It is a genetically heterogeneous 
disorder, typically attributable to pathogenic variants in 
genes encoding cardiac sarcomere proteins, predominantly 
MYBPC3 and MYH7.2 Truncating variants in MYBPC3 are 
a well-recognized cause of HCM, and the majority are con-
sidered to cause autosomal dominant disease with high 
age-related penetrance; consequently, such variants are 
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A 25 base pair deletion located within intron 32 of 
MYBPC3 (MYBPC3Δ25), the c.3628-41_3628-17del 
variant, is a notable exception. Detected in 4% to 8% of 
individuals of South Asian ancestry,3,4 and with an esti-
mated 100 million carriers worldwide, this common vari-
ant is considered to be associated with cardiomyopathy, 
with an almost 7-fold increased risk of cardiomyopathy 
in heterozygous carriers.3 Although previous studies have 
considered the possibility that MYBPC3Δ25 lies in linkage 
disequilibrium with another MYBPC3 variant that causes 
or contributes to disease risk,3,4 comprehensive analyses 
in large patient cohorts have not been performed.
Here, using genetic data from 2 large HCM cohorts, 
we present data suggesting that MYBPC3Δ25 is not a 
pathogenic risk factor in HCM. Rather, the increased 
frequency of this variant in South Asian cardiomyopathy 
cohorts reflects the enrichment of a derived haplotype, 
which bears both the common MYBPC3Δ25 variant and 
a rare pathogenic variant, MYBPC3 c.1224-52G>A. 
Additionally, we find that MYBPC3 c.1224-52G>A—an 
intronic variant that is not routinely detected on gene 
panel or exome sequencing—is the single most common 
pathogenic variant in individuals of South Asian ancestry 
in our cohort and the second most common in individuals 
of European ancestry.
METHODS
The complete methods are available in Materials in the Data 
Supplement. Due to the confidential nature of some of the 
research materials supporting this publication, not all of the 
data can be made accessible to other researchers. Please con-
tact the corresponding author for more information. The study 
was approved by the local ethics committees, and all patients 
signed an informed consent.
RESULTS
Oxford Medical Genetics Laboratory 
Demographic and Clinical Details
Within the Oxford Medical Genetics Laboratory (OMGL) 
cohort, demographic information was available for 98.0% 
of individuals (2703/2757). The majority of referrals 
were provided by inherited cardiac condition centers 
within the United Kingdom (80.1%; 2166/2757). The 
average age was 54.5 years (±16.2), and 68.4% were 
men (n=1845; Table 1). No self-identified, or genetically 
derived, ancestry information was available.
HCMR Demographic and Clinical Details
Within the HCMR cohort, the average age was 49.5 
years (±11.3), and 71.4% were men. Genetically derived 
ancestry predictions, determined through principal com-
ponents analysis, demonstrated European ancestry in 
78.3%, African ancestry in 9.0%, and South Asian ances-
try in 5.1% of individuals (Table 1).
Population Frequency of MYBPC3Δ25
In the Genome Aggregation Database (gnomAD; v2.1.1), 
6.2% of individuals ascribed South Asian ancestry were 
heterozygous for the MYBPC3Δ25 variant (943/15 296 
[95% CI, 5.7%–6.5%]), 0.1% were homozygous (19). 
This is consistent with previous studies that have 
reported frequencies ranging from 2% to 8%.3,4 The 
MYBPC3Δ25 variant is highly specific to individuals of 
South Asian ancestry: 98.1% (95% CI, 97.0%–98.9%) 
of MYBPC3Δ25 variant carriers within gnomAD are 
derived from a South Asian population (Table 2).
Oxford Clinical Laboratory Cohort
In the OMGL HCM cohort, pathogenic variants were 
detected in 17.1% (471/2757), likely pathogenic vari-
ants in 6.9% (191/2757), and variants of uncertain 
significance in an additional 14.2% (392/2757) of 
individuals. A summary of the most frequently detected 
variants is presented in Table I in the Data Supplement. 
Nonstandard Abbreviations and Acronyms
gnomAD Genome Aggregation Database
HCM hypertrophic cardiomyopathy
HCMR Hypertrophic Cardiomyopathy Registry
OMGL Oxford Medical Genetics Laboratory
Table 1. Demographic Summary for OMGL and HCMR 
Cohorts
OMGL HCMR
Total, n 2757 2636
Age, y (SD) 54.5 (16.3) 49.5 (11.3)
Men 1845 (68.4%) 1893 (71.4%)
Ancestry
 AFR NA 239 (9.0%)
 AMR NA 135 (5.1%)
 EAS NA 68 (2.6%)
 EUR NA 2074 (78.3%)
 SAS NA 134 (5.1%)
Variant carriers
 P 471 (17.1%) 572 (21.6%)
 LP 191 (6.9%) 216 (8.2%)
 VUS 392 (14.2%) 379 (14.3%)
 Negative 1703 (61.8%) 1483 (56.0%)
Ancestry codes as per the International Genome Sample Resource: AFR 
indicates African; AMR, Ad Mixed American; EAS, East Asian; EUR, European; 
and SAS, South Asian. Counts for individuals with P, LP, or VUS included. HCMR 
indicates Hypertrophic Cardiomyopathy Registry; LP, likely pathogenic; NA, not 
available; OMGL, Oxford Medical Genetics Laboratory; P, pathogenic; and VUS, 
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0.7% (20/2757) of individuals were heterozygous for 
the MYBPC3Δ25 variant. In 50.0% (10/20) of individu-
als heterozygous for MYBPC3Δ25, a pathogenic or likely 
pathogenic sarcomeric gene variant was also detected; 
variants of uncertain clinical significance were detected 
in an additional 3 individuals (15.0%, 3/20; Table 3). Of 
these accompanying variants, MYBPC3 c.1224-52G>A 
was the most frequently observed, found in 30.0% 
(6/20) of individuals heterozygous for MYBPC3Δ25.
HCMR Cohort
In the HCMR cohort, pathogenic variants were detected 
in 21.7% (572/2636), likely pathogenic variants in 8.2% 
(216/2636), and variants of uncertain significance in an 
additional 14.4% (379/2636) of individuals. A summary 
of the most frequently detected variants is presented in 
Table I in the Data Supplement. Overall, 0.7% (18/2636) 
of individuals were heterozygous for the MYBPC3Δ25 
variant; no homozygous individuals were detected; 17 
MYBPC3Δ25 variant carriers were ascribed as South 
Asian ancestry by genetic principal components analysis 
(94.4%, 17/18). The carrier frequency for MYBPC3Δ25 
within the HCMR South Asian ancestry group was 12.7% 
([95% CI, 8.1%–19.4%] 17/134).
In 58.8% (10/17) of South Asian individuals hetero-
zygous for MYBPC3Δ25, a pathogenic variant in one of the 
sarcomeric genes was detected (Table 3). An additional 
2 individuals were found to have variants of uncertain 
clinical significance (11.8%, 2/17). Replicating findings 
from our discovery cohort, the c.1224-52G>A variant 
was the most frequent, found in 29.4% (5/17) of South 
Asian individuals heterozygous for MYBPC3Δ25.
Overall, including the MYBPC3 c.1224-52G>A vari-
ant, 25.4% ([95% CI, 18.8–33.4] 34/134) of HCMR pro-
bands ascribed South Asian ancestry had a pathogenic 
or likely pathogenic sarcomeric gene variant. An addi-
tional 15.6% ([95% CI, 10.5–22.8] 21/134) harbored 
a variant of uncertain significance. This is comparable to 
the detection rate in the OMGL cohort and to previously 
published cohorts.2,5
Direct comparison of the proportion of heterozy-
gous MYBPC3Δ25 variant carriers between the HCMR 
(17/134) and gnomAD (943/15 296) South Asian 
cohorts indicated a 2-fold enrichment within HCM cases 
(odds ratio [OR], 2.1 [95% CI, 1.2–3.4]; P=0.008). When 
HCMR probands with the MYBPC3Δ25/−52 haplotype 
were excluded, no difference was observed (OR, 0.96 
[95% CI, 0.40–1.95]; P=1.0). Exact multivariate logistic 
regression, of individuals of South Asian ancestry from 
the HCMR and BioResource for Rare Disease cohorts 
(Table 4), provided evidence in support of disease associ-
ation for the MYBPC3 c.1224-52G>A variant (OR, 15.90 
[95% CI, 2.05–∞]; P=0.003) but not the MYBPC3Δ25 
variant (OR, 1.76 [95% CI, 0.77–4.36]; P=0.15). The 
significance of the MYBPC3 c.1224-52G>A association 
adjusted for the MYBPC3Δ25 variant was confirmed using 
an exact Mantel-Haenszel test (P=0.003).
In individuals of South Asian ancestry in the HCMR 
cohort, the MYBPC3 c.1224-52G>A variant was found 
Table 3. Pathogenic, Likely Pathogenic, and Variants of Uncertain Significance Accompanying 
MYBPC3 in Individuals From Both the OMGL and HCMR Cohorts
Gene Variant Variant Classification
Frequency in Individuals 
Heterozygous for MYBPC3Δ25bp
OMGL
 MYBPC3 c.1224-52G>A Pathogenic 6/20
 MYBPC3 c.1227-13G>A Pathogenic 1/20
 MYBPC3 c.2827C>T p.(Arg943Ter) Pathogenic 1/20
 MYH7 c.2770G>A p.(Glu924Lys) Pathogenic 1/20
 MYBPC3 c.2308G>A p.(Asp770Asn) Likely pathogenic 1/20
 MYBPC3 c.2030C>T p.(Pro677Leu) VUS 1/20
 MYH7 c.3931C>G p.(Gln1311Glu) VUS 1/20
 MYH7 c.436A>G p.(Lys146Glu) VUS 1/20
HCMR
 MYBPC3 c.1224-52G>A Pathogenic 5/18
 MYBPC3 c.1227-13G>A Pathogenic 1/18
 MYBPC3 c.821+2T>C Pathogenic 1/18
 MYH7 c.1988G>A p.(Arg663His) Pathogenic 1/18
 MYH7 c.2221G>A p.(Gly741Arg) Pathogenic 1/18
 MYH7 c.5065C>T p.(Arg1689Cys) VUS 1/18
  MYH7 c.170G>A p.(Gly57Asp) VUS 1/18
NCBI transcript IDs: MYBPC3 NM_000256.3 and MYH7 NM_000257.2. HCMR indicates Hypertrophic Cardiomyopathy Registry; 
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to occur on the second most commonly observed 
MYBPC3Δ25 haplotype (Figure 1). Hence, there is 
evidence of strong linkage disequilibrium between 
MYBPC3Δ25 and MYBPC3 c.1224-52G>A (D′=0.81 
and r2=0.22; Figure I in the Data Supplement; Table II 
in the Data Supplement). In South Asian individuals, the 
MYBPC3 c.1224-52G>A variant also occurred on a hap-
lotype that did not include the MYBPC3Δ25 variant.
Investigating the Pathogenicity of MYBPC3 
c.1224-52G>A
The MYBPC3 c.1224-52G>A variant 
(Chr11[GRCh37]:g.47364865C>T, NM_000256.3) was 
detected in 32 of 2757 (1.2% [95% CI, 0.8%–1.6%]) 
probands in the OMGL cohort and in 23 of 2636 (0.9% 
[95% CI, 0.6%–1.2%]) probands in the HCMR cohort. 
A 2-sample test for equality of proportions, with conti-
nuity correction, suggests the minor allele frequencies 
derived from OMGL and HCMR are equivalent (P=0.98). 
No other pathogenic or likely pathogenic sarcomere 
gene variants were detected in these cases. Within the 
OMGL cohort, MYBPC3 c.1224-52G>A was confirmed 
to cosegregate with HCM in 4 families (Figure II in the 
Data Supplement); in 3, it was detected in the proband 
and 2 other affected relatives. Within the wider HCMR 
and OMGL populations, MYBPC3 c.1224-52G>A was 
found to occur on 2 additional haplotypes, distinct from 
the 2 South Asian haplotypes, which argues against a 
unique founder mutation.
The c.1224-52G>A variant occurs once within 
76 048 nonoverlapping individuals, present within gno-
mAD (v.2.1.1) and NHLBI Trans-Omics for Precision 
Medicine (https://bravo.sph.umich.edu/freeze5/hg38/), 
indicating a global minor allele frequency, incorporat-
ing all available ancestral groups, of 6.57×10−6. A com-
parison of the proportion of individuals heterozygous for 
this variant in the combined OMGL and HCMR cohorts 
(55/5393), against these reference populations, gener-
ates an extreme effect size (OR, 780 [95% CI, 135–
16 384]; P=9.74×10−64).
In silico splice site tools predict that c.1224-
52G>A introduces a cryptic splice acceptor site in 
intron 13 (NM_000256.3), 50 nucleotides upstream 
(5′) of the native site. Polymerase chain reac-
tion of cDNA reverse transcribed from RNA from 2 
Table 4. South Asian Cases vs Controls









Cases 5 12 1 116
Controls 0 21 0 357
A 2-by-2-by-2 contingency table reporting counts of genotypes for cases vs controls by indel carriers vs noncarriers by −52 carriers vs 
noncarriers for individuals of South Asian ancestry. Case data derived from HCMR and control data derived from BRRD. BRRD indicates 
BioResource for Rare Disease cohort; and HCMR, Hypertrophic Cardiomyopathy Registry.
Figure 1. Haplotype structure across MYBPC3.
Each horizontal line (denoted A–G) represents a unique haplotype observed across MYBPC3 with the South Asian population 
derived from the Hypertrophic Cardiomyopathy Registry cohort (n=134). Genetic markers denoted using the following nomenclature: 
<chromosome>_<GRCh37 position>_<reference allele>_<alternate allele>. Grey indicates the presence of the ancestral allele. Blue shading 
indicates the presence of an alternate allele. The MYBPC3Δ25 allele (11_47353825_A_del25) is emphasized using a darker shade of blue. Red 
shading represents the presence of the MYBPC3−52 allele (11_47364865_C_T). Haplotype A is composed entirely of reference alleles and is 
present in 49.9% of the cohort. MYBPC3Δ25 is present on haplotypes D and F. Haplotype F also includes MYBPC−52. Figure generated from 




 http://ahajournals.org by on Septem
ber 24, 2021
Harper et al South Asian MYBPC3Δ25 Intronic Deletion in HCM
Circ Genom Precis Med. 2020;13:e002783. DOI: 10.1161/CIRCGEN.119.002783 June 2020 106
individuals with the c.1224-52G>A variant generated 
an aberrant product. Sequencing of this product con-
firmed in silico predictions and showed inclusion of 
50 intronic nucleotides in the transcript (Figure 2). 
Inclusion of these nucleotides is predicted to lead to 
a frameshift in the amino acid sequence and insertion 
of a premature termination codon at position 438 
(p.Ser408fs*31).
Pathogenicity Classification for MYBPC3 
c.1224-52G>A
Using the American College of Medical Genetics frame-
work,6 the MYBPC3 c.1224-52G>A variant was classi-
fied as pathogenic based on the following criteria: PS3: 
RNA studies have provided evidence of an aberrant effect 
on splicing (our analyses and published data7); PS4: the 
variant is significantly more frequent in probands with 
HCM than in population controls; PM2: the variant is very 
rare in the wider population; and PP1: there is evidence 
of cosegregation with HCM in multiple families (4 in our 
cohort and published data7).
DISCUSSION
When the MYBPC3Δ25 variant was first reported to be 
associated with cardiomyopathy in the South Asian 
population, it was thought likely to have a direct role in 
disease pathogenesis; since the initial report, it has come 
to be considered as one of the most compelling exam-
ples of a common, low-penetrance variant contributing 
to the genetic architecture of HCM.3,8–12 Genetic analy-
ses undertaken in this study challenge these previous 
assertions and show that the MYBPC3Δ25 variant does 
not directly confer an increased risk of cardiomyopa-
thy but instead acts as a proxy marker for a rare, large 
effect size, intronic pathogenic variant, MYBPC3 c.1224-
52G>A (Figure 3). Consequently, we conclude that het-
erozygosity for the MYBPC3Δ25 common variant is not 
pathogenic for HCM.
Through RNA studies and segregation analyses, we 
provide robust evidence to support the pathogenicity of 
the MYBPC3 c.1224-52G>A variant. This variant has 
previously been described in the literature as a patho-
genic variant7; however, neither its high prevalence nor 
its relationship with MYBPC3Δ25 has been reported. Our 
analyses reveal MYBPC3 c.1224-52G>A to be a recur-
rent variant, and one of the most frequent pathogenic 
variants across all known HCM genes in both European 
and South Asian populations, comparable to other well-
established recurrent and founder pathogenic variants 
(eg, MYBPC3 c.2373dup13 and MYBPC3 p.Glu258Lys2), 
and exceeded only by the MYBPC3 p.Arg502Trp variant, 
the most common pathogenic variant in HCM.2,5,14 Fur-
ther, the MYBPC3 c.1224-52G>A variant has a strikingly 
Figure 2. RNA studies MYBPC3 c.1224-52G>A variant.
A, Gel fractionation of RT-PCR products of lymphocyte-derived RNA from 2 affected individuals heterozygous for the MYBPC3 c.1224-
52A>G. Affected individuals in lanes 2 and 4 (corresponding reverse transcriptase negative controls in lanes 3 and 5) and controls in lanes 
6 and 8 (corresponding reverse transcriptase negative controls in lanes 7 and 9). Blue arrow corresponds with normal fragment (323 bp), as 
seen in controls, and the red arrow corresponds to the aberrant fragment (375 bp). A 100 base pair ladder was used in lanes 1 and 11 (500 
bp [dense band], 400 bp, and 300 bp bands shown). B and C, Sanger sequencing of wild-type (B) and aberrant polymerase chain reaction 
product derived from cDNA of an affected individual harboring MYBPC3 c.1224-52A>G (C) indicates a 50-nucleotide intronic inclusion, 
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high OR for disease (≈700), suggesting that it is a high 
penetrance allele.
Haplotype analyses indicate that an ancestral 
MYBPC3 c.1224-52G>A variant arose on a haplotype 
bearing the common MYBPC3Δ25 variant and that the 
reported association between MYBPC3Δ25 and HCM in 
the South Asian population was due to the increased 
frequency of the derived MYBPC3Δ25/−52 haplotype, 
which had not previously been differentiated from the 
common MYBPC3Δ25 haplotype. In our cohort, after 
accounting for the MYBPC3Δ25/−52 haplotype, the fre-
quency of the MYBPC3Δ25 allele appears equivalent 
between HCM cases and reference controls, which 
casts doubt upon previous pathogenic inferences from 
risk associations and suggests that it is not clinically 
appropriate to type the MYBPC3Δ25 in isolation. Indeed, 
the ability to detect the MYBPC3Δ25/−52 haplotype is 
critical not only for individuals with a clinical diagno-
sis of HCM but for the vast majority of the 100 million 
individuals of South Asian ancestry heterozygous for 
the MYBPC3Δ25 alone, who would previously have been 
declared at increased risk of HCM.
Limitations
Our conclusions rely on the observed MYBPC3Δ25 and 
MYBPC3Δ25/−52 haplotype frequencies being represen-
tative of the wider South Asian population. Here, direct 
evaluation of MYBPC3Δ25 and MYBPC3Δ25/−52 and HCM 
disease risk has relied on analysis performed using indi-
viduals ascribed South Asian ancestry based on genetic 
principal components analysis from 2 independent, 
but relatively small, cohorts. Large reference cohorts, 
specifically gnomAD and Trans-Omics for Precision 
Medicine, were useful in quantifying the allele frequen-
cies of both MYBPC3Δ25 and MYBPC3 c.1224-52G>A 
but were not suitable for the direct evaluation of the 
MYBPC3Δ25/−52 haplotype, given the lack of individual-
level data.
Our case series comprised 2 large HCM cohorts 
with a combined total of 5394 HCM probands (OMGL, 
n=2757; HCMR, n=2636), representing the larg-
est published HCM cohort to date. MYBPC3Δ25 and 
MYBPC3Δ25/−52 haplotype frequencies were equivalent 
within these mixed ancestry HCM cohorts. Ancestry data 
were only available from the HCMR cohort, in which 134 
cases were defined as South Asian; additional analyses 
in other South Asian cohorts will refine MYBPC3Δ25/−52 
haplotype frequency estimates and allow more accurate 
quantification of the strength of the association of this 
haplotype to HCM in this population.
The findings in this study relate specifically to HCM. 
In the original case-control study by Dhandapany et al,3 
2 composite case groups were assembled that included 
individuals diagnosed with HCM (n=357), dilated car-
diomyopathy (n=395), and restrictive cardiomyopathy 
(n=15). While our findings refute a pathogenic role for 
the MYBPC3Δ25 variant in HCM, at present, our conclu-
sions do not extend to these other cardiomyopathies or 
to homozygosity for this variant. However, given current 
understanding of the diametrically opposing molecu-
lar mechanisms that underpin sarcomeric HCM and 
Figure 3. A reevaluation of the common MYBPC3Δ25bp intronic variant (MYBPC3Δ25) in the South Asian population.
The MYBPC3Δ25 is a common variant present in 4% to 8% of the South Asian population (estimated to be carried by ≈100 million people). 
In a cohort of South Asian hypertrophic cardiomyopathy (HCM) cases, we detected a rare derived haplotype, bearing both MYBPC3Δ25 and 
a pathogenic variant, MYBPC3 c.1224-52G>A. The rare MYBPC3Δ25/−52 haplotype is strongly associated with HCM with high penetrance. 
Haplotypes bearing MYBPC3Δ25 without the MYBPC3 c.1224-52G>A variant, which account for the vast majority of South Asian individuals 
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dilated cardiomyopathy,15–17 it seems unlikely that a 
single variant, such as MYBPC3Δ25, could cause both 
conditions. Further, truncating variants in MYBPC3 have 
only been associated with HCM and not primary dilated 
cardiomyopathy.2
Conclusions
The results of this study provide strong evidence to 
refute a direct pathogenic link between the MYBPC3Δ25 
variant and HCM risk; this is important for the very large 
number of South Asian individuals who will be found to 
have this variant when undergoing either targeted or 
genome-wide genetic analysis. Additionally, they high-
light MYBPC3 c.1224-52G>A as an important HCM 
variant. They also reiterate the importance of sequenc-
ing deeper intronic regions in the MYBPC3 gene, and, 
indeed, other cardiomyopathy genes where truncat-
ing variants are believed to cause the disease. Collec-
tively, these findings have significant implications for our 
understanding of the genetic architecture of HCM and 
for the clinical management of patients with HCM.
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